Why is Centenial Surgic falling/rising?

Recent Price Movement and Market Comparison

The stock opened sharply lower, registering a gap down of 4.89% and touched an intraday low of ₹96, trading within a narrow range of just ₹0.35. This limited price movement suggests a lack of strong buying interest to counter the selling pressure. Notably, Centenial Surgical Suture has underperformed its sector by 4.73% on the day, signalling relative weakness compared to its peers.

Over the past week and month, the stock has declined by 2.83% and 11.93% respectively, while the benchmark Sensex gained 0.79% and 0.95% in the same periods. Year-to-date, the stock has fallen sharply by 30.43%, contrasting with the Sensex’s positive return of 9.08%. This persistent underperformance highlights ongoing challenges faced by the company.

Technical Indicators and Investor Participation

Technically, the stock is trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also waned considerably, with delivery volumes on 20 Nov plunging by 86.32% compared to the five-day average. This decline in trading activity suggests reduced confidence among shareholders and a lack of fresh buying interest.

Fundamental Weaknesses Weighing on the Stock

Despite a seemingly attractive valuation with a Return on Capital Employed (ROCE) of 2.8% and an enterprise value to capital employed ratio of 1.1, the company’s fundamentals paint a concerning picture. Over the last five years, Centenial Surgical Suture has experienced a negative compound annual growth rate (CAGR) of -21.26% in operating profits, signalling deteriorating operational efficiency.

Profitability metrics remain subdued, with an average Return on Equity (ROE) of just 2.19%, indicating limited returns generated on shareholders’ funds. The company’s ability to service debt is also weak, reflected in a poor EBIT to interest coverage ratio of 1.33, raising concerns about financial stability and risk.

Recent Financial Performance and Market Position

The company reported flat results in the September 2025 half-year, with ROCE at a low 2.96%. Quarterly net sales stood at ₹13.46 crores, declining by 5.68%, further underscoring the challenges in revenue growth. Over the past year, profits have plummeted by 301%, a stark indicator of operational difficulties that have likely contributed to the stock’s negative returns of -23.20% over the same period.

This contrasts sharply with the broader market, where the BSE500 index has delivered returns of 8.59% in the last year, highlighting Centenial Surgical Suture’s significant underperformance relative to its peers and the market at large.

Investor Sentiment and Outlook

Investor sentiment appears cautious, with majority shareholding held by non-institutional investors, which may limit the stock’s liquidity and institutional support. The combination of weak long-term growth, poor profitability, and subdued sales growth has led to a lack of confidence among market participants, reflected in the stock’s persistent underperformance and recent price decline.

While the valuation metrics suggest the stock is trading at a discount compared to peers, the fundamental weaknesses and deteriorating financial performance continue to weigh heavily on the share price. Until there is a clear turnaround in profitability and operational metrics, the stock is likely to remain under pressure.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →